Linked Life Data

16497827

Source:http://linkedlifedata.com/resource/pubmed/id/16497827

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2006-9-12
pubmed:abstractText
Randomized clinical trials of neo-adjuvant cisplatin-based combination chemotherapy for locally advanced muscle invasive bladder cancer has shown a survival benefit over cystectomy alone. Pathologic complete response (pT0) after neo-adjuvant chemotherapy is emerging as a potentially important surrogate clinical end point. Future clinical trials incorporating targeted therapies with novel clinical end points may accelerate development of therapeutic strategies for locally advanced muscle invasive bladder cancer. Furthermore, evaluation of molecular markers may further help to stratify patients to a risk adapted approach.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1360-9
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead.
pubmed:affiliation
Department of Medicine, Division of Hematology/Oncology, Medical University of South Carolina, SC 29425, USA.
pubmed:publicationType
Journal Article, Review